GC-022

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameGC-022
Drug Alias NameCD19 CD22 Bispecific CAR-Modified T CellsCD19 CD22 bispecific CAR-T cellsGC-022GC-022F
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD19 +[4] 
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGracell Biotechnologies (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Tongren Hospital, Cmu
Inactive CompaniesGracell Biotechnology Ltd
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsHematologic NeoplasmsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A